BiotechTube
Home/Alterity Therapeutics/Thomas C. Scanlin, Ph.D.
TC

Thomas C. Scanlin, Ph.D.

Chief Medical Officer

Alterity Therapeutics

Therapeutic Areas

NeuroscienceNeurodegenerative Diseases

Alterity Therapeutics Pipeline

DrugIndicationPhase
ATH434Multiple System Atrophy (MSA)Phase 2

Leadership Team at Alterity Therapeutics

DS
David Stamler, M.D.
Chief Executive Officer
GK
Geoffrey Kempler
Non-Executive Chairman
DA
Dr. Andrew S. L. Chan
Chief Scientific Officer
View full Alterity Therapeutics profile